Evidence map›Paper›PMID 38662145›Full record

ArticleRheumatology and therapy2024

Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European Initiative.

Iris Verbinnen, Emilio Monte-Boquet, Detlev Parow, Fabienne Lacombe, Andrew Pothecary, Arno W R van Kuijk, Laura Harrington, Edita Müllerová, Andreas Pinter, Ulrike Erstling and 2 more

Open access · goldAbstract read
In one paragraph

Article in Rheumatology and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 5 countries.

Iris VerbinnenLaboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, Leuven Brain Institute, University of Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3681-1628
Emilio Monte-BoquetPharmacy Department, Drug Clinical Area, Hospital Universitari i Politècnic la Fe, Valencia, Spain.ORCID http://orcid.org/0000-0001-5352-2601
Detlev ParowFormerly Department of Medicines, Therapeutic Appliances and Remedies, DAK-Gesundheit, Hamburg, Germany.
Fabienne LacombeAssociation France Spondyloarthrites, Tulle, France.
Andrew PothecaryDepartment of Rheumatology, Royal Cornwall Hospitals NHS Trust, Truro, UK.ORCID http://orcid.org/0000-0003-2297-4159
Arno W R van KuijkAmsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands.
Laura HarringtonOgilvy Health, Oxford, UK.
Edita MüllerováRevma Liga Česká Republika, z.s., Prague, Czech Republic.
Andreas PinterDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0002-1330-1502
Ulrike ErstlingFachverband Rheumatologische Fachassistenz e.V., Bergisch Gladbach, Germany.ORCID http://orcid.org/0009-0000-3565-2410
Andrea TomasiniNational Association of People with Rheumatological and Rare Diseases, APMARR, Lecce, Italy.
Philip S HelliwellLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. p.helliwell@leeds.ac.uk.ORCID http://orcid.org/0000-0002-4155-9105
DAK-Gesundheit (Germany) · DEGoethe University Frankfurt · DEHospital Universitari i Politècnic La Fe · ESKU Leuven · BEReade · NLRoyal Cornwall Hospital Trust · GBUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPsoriatic arthritis (PsA) is a complex, progressive, and often debilitating disease. Despite recent advances in treatment, numerous unmet needs in patient care persist. Rheumacensus is a multistakeholder, pan-European initiative designed to identify ways to elevate the standard of care (SoC) and treatment ambition for patients with PsA, using the perspectives of three key stakeholder groups: patients, healthcare professionals (HCPs) and payors.

methodsRheumacensus followed three phases: an insights-gathering workshop to identify current unmet needs in PsA and an area of focus for the project, a modified Delphi process to gain consensus on improvements within the agreed area of focus, and a Consensus Council (CC) meeting which used consensus statements as inspiration to generate 'Calls to Action' (CTA)-practical measures which, if implemented, could elevate the SoC for patients with PsA.

resultsThe Rheumacensus CC consisted of four patient representatives, four HCPs and four payors. All 12 members completed all three Delphi e-consultations. The shared area of focus that informed the Delphi process was "patient empowerment through education on the disease and treatment options available, to enable patient involvement in management". Four key themes emerged from the Delphi process: patient empowerment, patient knowledge and sources of education, patient-HCP consultations, and optimal initial treatment. Statements within these themes informed 12 overarching CTA, which focus on the need for a multistakeholder approach to implementing a paradigm shift towards patient-centred care and improved outcomes for patients with PsA.

conclusionRheumacensus has identified shortcomings in the current SoC for patients with PsA and provides a foundation for change through practical CTA. It is hoped that all stakeholders will now take practical steps towards implementing these CTA across Europe to elevate the SoC for patients with PsA.

Indexed as

CommunicationEducationPatient-centricPatient empowermentPsoriatic arthritisStandard of care

Identifiers

PMID38662145
PMCPMC11111599
OpenAlexW4395465303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.